Literature DB >> 6168630

Tallysomycin, a new antitumor antibiotic complex related to bleomycin. IV. New biosynthetic derivatives of tallysomycin.

T Miyaki, O Tenmyo, K Numata, K Matsumoto, H Yamamoto, Y Nishiyama, M Ohbayashi, H Imanishi, M Konishi, H Kawaguchi.   

Abstract

A series of new biosynthetic derivatives of tallysomycins A and B were obtained by precursor amine-feeding fermentation. Certain diamines were incorporated into tallysomycins as the terminal amine moiety affording two classes of biosynthetic derivatives, with or without the Beta-lysine moiety in the subterminal position. Among 21 derivatives prepared, tallysomycin S10b was selected for further studies in view of its favorable therapeutic indices.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168630     DOI: 10.7164/antibiotics.34.658

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  6 in total

1.  A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine.

Authors:  R C Gaver; C W Dixon; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Enantiomeric free radicals and enzymatic control of stereochemistry in a radical mechanism: the case of lysine 2,3-aminomutases.

Authors:  E Behshad; F J Ruzicka; S O Mansoorabadi; D Chen; G H Reed; P A Frey
Journal:  Biochemistry       Date:  2006-10-24       Impact factor: 3.162

3.  Quantitative measurement of single- and double-strand breakage of DNA in Escherichia coli by the antitumor antibiotics bleomycin and talisomycin.

Authors:  C K Mirabelli; C H Huang; R G Fenwick; S T Crooke
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Functional characterization of tlmK unveiling unstable carbinolamide intermediates in the tallysomycin biosynthetic pathway.

Authors:  Liyan Wang; Meifeng Tao; Evelyn Wendt-Pienkoski; Ute Galm; Jane M Coughlin; Ben Shen
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

5.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 6.  Rheumatological manifestations in inborn errors of immunity.

Authors:  Kaan Boztug; Seza Özen; Sevgi Köstel Bal; Julia Pazmandi
Journal:  Pediatr Res       Date:  2019-10-03       Impact factor: 3.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.